Galecto, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Galecto, Inc. | GLTO - NASDAQ |
$14.00-$16.00 | $15.00 | $15.00 | 5.7 million | 10/29/2020 |
| BofA Securities, SVB Leerink, Credit Suisse | ||||||
Co-Manager(s): Kempen & Co | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-10-07 Terms Added 2020-10-22 | ||||||
Galecto, Inc. Quote & Chart - Click for current quote - GLTO
IPO Boutique aggregates information on public companies and private companies, such as "GLTO" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Galecto, Inc. (adapted from Galecto, Inc. prospectus):
They are a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "GLTO" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.